# Nuclide record girentuximab-zr89 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/girentuximab-zr89/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "girentuximab-zr89" ;
  schema:name "Zirconium-89 girentuximab"@en ;
  schema:alternateName "89Zr-DFO-girentuximab"@en, "Zircaix"@en ;
  schema:description "Zirconium-89 girentuximab is Telix's PET scan that tells whether a kidney mass is clear cell renal cell carcinoma without a biopsy; the phase 3 ZIRCON trial met its endpoints in 2023 and the product is under regulatory review."@en ;
  schema:url <https://nuclide.cc/drugs/girentuximab-zr89/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=TLX250-CDx> ;
  nuclide:status "phase-3" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:modality "PET imaging antibody labelled with zirconium-89" ;
  nuclide:related <https://nuclide.cc/isotopes/zr-89/> ;
  nuclide:indications <https://nuclide.cc/indications/rcc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/immuno-pet/>, <https://nuclide.cc/technologies/pet/> ;
  nuclide:companies <https://nuclide.cc/companies/telix/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06750419/> .